{"slug":"api-magentlab-com-api-calc-who-pv-698a96","title":"WHO 2016 polycythemia vera criteria (Arber 2016)","host":"api.magentlab.com","method":"POST","resource":"https://api.magentlab.com/api/calc/who_pv","category":"other","description":"WHO 2016 polycythemia vera criteria (Arber 2016). Met when all three majors hold, or when major 1 and major 2 hold with subnormal EPO. Major 1 is male Hb >16.5 g/dL or Hct >49%, female Hb >16.0 or Hct >48%, or increased red-cell mass. Major 2 is caller-assigned marrow panmyelosis. Major 3 is JAK2 V6","price_listed":0.005,"price_asked":0.007,"state":"overcharges","state_label":"Asked 1.4x its listed price for its own example","checks_7d":1,"answered_7d":1,"latency_ms_median":327,"reported_calls_30d":0,"reported_payers_30d":0,"networks":["eip155:8453"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"body":{"items":[{"bone_marrow_panmyelosis":false,"hematocrit_percent":45,"hemoglobin_g_dl":15,"increased_red_cell_mass":false,"jak2_v617f_or_exon12":false,"sex":"male","subnormal_epo":false},{"bone_marrow_panmyelosis":false,"hematocrit_percent":45,"hemoglobin_g_dl":15,"increased_red_cell_mass":false,"jak2_v617f_or_exon12":false,"sex":"male","subnormal_epo":false}]},"method":"POST","type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"body":{"additionalProperties":false,"properties":{"items":{"items":{"properties":{"bone_marrow_panmyelosis":{"description":"WHO 2016 marrow major as assigned by the caller (age-adjusted hypercellularity with panmyelosis, including pleomorphic mature megakaryocytes). true or false. magent does not read slides.","type":"boolean"},"hematocrit_percent":{"description":"Hematocrit percent (10-70). Major 1 meets when male >49 or female >48. Optional when hemoglobin_g_dl is sent or increased_red_cell_mass is true. magent does not assay hematocrit.","type":"number"},"hemoglobin_g_dl":{"description":"Hemoglobin in g/dL (3-22). Major 1 meets when male >16.5 or female >16.0. Optional when hematocrit_percent is sent or increased_red_cell_mass is true. At least one of hemoglobin_g_dl, hematocrit_percent, or increased_red_cell_mass true is required. magent does not assay hemoglobin.","type":"number"},"increased_red_cell_mass":{"description":"Increased red-cell mass as assigned by the caller (Arber 2016 WHO 2016 major 1 alternative to Hb/Hct). true or false. true meets major 1 even when Hb/Hct are omitted or below threshold. magent does not measure red-cell mass.","type":"boolean"},"jak2_v617f_or_exon12":{"description":"JAK2 V617F or JAK2 exon 12 mutation as assigned by the caller (Arber 2016 WHO 2016 major 3). true or false. magent does not sequence JAK2.","type":"boolean"},"sex":{"description":"female or male (Arber 2016 WHO 2016 PV hemoglobin/hematocrit thresholds). Required even when only increased_red_cell_mass is used. Assigned by the caller.","enum":["female","male"],"type":"string"},"subnormal_epo":{"description":"Subnormal serum erythropoietin as assigned by the caller (Arber 2016 WHO 2016 minor criterion). true or false. magent does not assay EPO.","type":"boolean"}},"required":["sex","increased_red_cell_mass","bone_marrow_panmyelosis","jak2_v617f_or_exon12","subnormal_epo"],"type":"object"},"maxItems":25,"minItems":1,"type":"array"}},"required":["items"],"type":"object"},"headers":{"additionalProperties":{"type":"string"},"type":"object"},"method":{"const":"POST","type":"string"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-09-28","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.007,"price_match":false,"latency_ms":327,"error":null}],"description_full":"WHO 2016 polycythemia vera criteria (Arber 2016). Met when all three majors hold, or when major 1 and major 2 hold with subnormal EPO. Major 1 is male Hb >16.5 g/dL or Hct >49%, female Hb >16.0 or Hct >48%, or increased red-cell mass. Major 2 is caller-assigned marrow panmyelosis. Major 3 is JAK2 V617F or exon 12. Not a medical device, not a WHO diagnosis, and not WHO 2022. magent does not assay EPO or sequence JAK2.","last_updated":"2026-09-28T15:10:14.813Z","schemes":["exact"]}